Kristen Harrington-Smith

Ms. Harrington-Smith joined ADC Therapeutics in November 2022 with over 20 years of experience in the pharmaceutical industry. Most recently, she served as Chief Commercial Officer at ImmunoGen.

Prior to joining ImmunoGen, Ms. Harrington-Smith held roles of increasing responsibility at Novartis Pharmaceuticals including US Commercial Head of Hematology, where she led the commercial teams responsible for a portfolio of therapies in both malignant and non-malignant hematologic diseases including acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, sickle cell disease, and paroxysmal nocturnal hemoglobinuria. Prior to this role, she was responsible for the commercial launch of Kymriah®, the first CAR-T-cell therapy for the treatment of diffuse large B-cell lymphoma and pediatric acute lymphoblastic leukemia, building the management, sales, marketing, and market access teams. She currently serves on the board of directors of eFFECTOR Therapeutics.

Ms. Harrington-Smith received a BA from Williams College and an MBA from the Kenan-Flagler Business School at the University of North Carolina.